Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Roivant, Organon
Roivant Flips a Skin Drug to Organon
Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, and then selling them for big returns.
Roivant's Sale Of Dermavant To Organon: A Strategic Win-Win In Atopic Dermatitis
Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click here to read my most recent analysis.
Organon makes $1.2bn play for Roivant’s immuno-dermatology subsidiary
As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis.
Organon to buy Roivant's dermatology unit for up to $1.2 billion
Shares of
Roivant
, which owns 86% of Dermavant as of March 31, 2024, and was founded by former Republican presidential candidate Vivek Ramaswamy, were up 1.7% at $12.26 in early trading. However,
Organon
was down 1.4%. Dermavant's Vtama cream, approved by ...
Roivant dermatology subsidiary to be acquired by Organon
The deal hands Organon a psoriasis and eczema cream called Vtama, while Roivant will get more cash to fund its R&D plans.
Organon to Buy Roivant's Dermavant Unit in Deal Worth Up to $1.2 Billion
Organon has agreed to buy medical dermatology company Dermavant Sciences, a majority-owned unit of Roivant Sciences, in a deal worth up to $1.2 billion. Organon on Wednesday said it will make an up-front payment of $175 million, along with up to $1.025 billion in milestone payments.
Organon to buy skin therapy developer Dermavant for up to $1.2 billion
(Reuters) -Healthcare company Organon said on Wednesday it has agreed to acquire skin therapy developer Dermavant, a unit of Roivant, for up to $1.2 billion. Organon will make an upfront payment of $175 million,
FiercePharma
5d
Organon pays up to $1.2B to acquire Dermavant and its steroid-free skin cream Vtama
Organon
is set to acquire
Roivant
’s immuno-dermatology subsidiary Dermavant for up to $1.2 billion, the companies ...
5d
Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B
Organon & Co (NYSE:OGN) has agreed to acquire Roivant Sciences Ltd’s (NASDAQ:ROIV) Dermavant Sciences Ltd, which is focused ...
15h
Regulatory News | Today's Latest Stories | Reuters
Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...
ENDPOINTS NEWS
5d
Roivant makes another deal, selling Dermavant to Organon for up to $1.2B
Roivant is once again reaping the benefits of its bespoke business model. This time, it's selling Dermavant to Organon for up ...
NJBIZ
4d
Organon to acquire Dermavant in $1.2B deal
The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.
Pharmabiz
3d
Organon to buy Dermavant Sciences including its innovative dermatologic therapy, Vtama cream 1% to treat plaque psoriasis
Basel, Switzerland Friday, September 20, 2024, 13:00 Hrs [IST] ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback